Health & Fitness
Health and Fitness
Health and Fitness
Thu, August 30, 2012Wed, August 29, 2012Tue, August 28, 2012Mon, August 27, 2012Sun, August 26, 2012Sat, August 25, 2012Fri, August 24, 2012Thu, August 23, 2012Wed, August 22, 2012Tue, August 21, 2012Mon, August 20, 2012Sat, August 18, 2012Fri, August 17, 2012Thu, August 16, 2012Wed, August 15, 2012Tue, August 14, 2012Mon, August 13, 2012Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
Published in Health and Fitness on Friday, August 24th 2012 at 5:20 GMT by Market Wire
Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference -- MENLO PARK, Calif., Aug. 24, 2012 /PRNewswire/ --
Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
MENLO PARK, Calif., Aug. 24, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: [ DEPO ]) today announced that it will be presenting at the Stifel Nicolaus Healthcare Conference in Boston.
The presentation at the Stifel Nicolaus conference is scheduled for 10:55 a.m. EDT (7:55 a.m. PDT) on Wednesday, September 5, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at [ www.depomed.com ]. A recording of the webcast will be archived for 30 days on the company's website.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with three approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Zipsor ®(diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, [ www.depomed.com ].
CONTACT:
August J. Moretti
Depomed, Inc.
650-462-5900
[ amoretti@depomed.com ]
SOURCE Depomed, Inc.
[ Back to top ]
RELATED LINKS
[ http://www.depomed.com ]
